Drug Trial Radar · NCT06598462
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
184
Actual
Start
Oct 16, 2024
Primary completion
Apr 30, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- Uniquity One (UNI)Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis.
Conditions
- Eosinophilic Esophagitis (EoE)
Interventions
Solrikitug Low DoseBiological
Solrikitug low dose subcutaneous injection
Solrikitug Mid DoseBiological
Solrikitug mid dose subcutaneous injection
Solrikitug High DoseBiological
Solrikitug high dose subcutaneous injection
PlaceboOther
Placebo subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Histological response of peak esophageal eosinophil per HPF count of ≤6Time frame: Week 24
- Change from baseline in DSQ (Dysphagia Symptom Questionnaire) scoreTime frame: Week 24
Locations
73 sites in 9 countries. Site status is shown where the registry gives one.
Research Site 1039
Dothan, Alabama
Research Site 1018
Glendale, Arizona
Research Site 1018
Peoria, Arizona
Research Site 1037
Scottsdale, Arizona
Research Site 1003
Tucson, Arizona
Research Site 1023
Englewood, California
Research Site 1005
Irvine, California
Research Site 1015
San Diego, California
Research Site 1034
Aurora, Colorado
Research Site 1027
Cromwell, Connecticut
Research Site 1040
Inverness, Florida
Research Site 1001
Jacksonville, Florida
Research Site 1049
Miami, Florida
Research Site 1007
Boise, Idaho
Research Site 1048
Glenview, Illinois
Research Site 1022
Iowa City, Iowa
Research Site 1033
Topeka, Kansas
Research Site 1032
Chevy Chase, Maryland
Research Site 1004
Boston, Massachusetts
Research Site 1024
Ann Arbor, Michigan
Research Site 1013
Wyoming, Michigan
Research Site 1006
Plymouth, Minnesota
Research Site 1042
Creve Coeur, Missouri
Research Site 1016
Reno, Nevada
Research Site 1045
Freehold, New Jersey
Research Site 1043
Jackson, New Jersey
Research Site 1026
Chapel Hill, North Carolina
Research Site 1021
High Point, North Carolina
Research Site 1012
Columbus, Ohio
Research Site 1020
Harrisburg, Pennsylvania
Research Site 1030
Philadelphia, Pennsylvania
Research Site 1014
Dallas, Texas
Research Site 1008
Houston, Texas
Research Site 1036
Pearland, Texas
Research Site 1041
Rockwell, Texas
Research Site 1002
Ogden, Utah
Research Site 1019
Salt Lake City, Utah
Research Site 1017
Sandy City, Utah
Research Site 1111
Maroochydore, Australia
Research Site 1107
Woolloongabba, Australia
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.